Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 9Lymphoma, Mantle-Cell 8Recurrence 7Lymphoma, Non-Hodgkin 5Lymphoma, B-Cell 5Lymphoma 4Dendritic Cell Sarcoma, Interdigitating 2Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1Immunoblastic Lymphadenopathy 1Cytokine Release Syndrome 1Aggression 1

Interventions

Cyclophosphamide 2sodium-iodide symporter 1ruxolitinib 1glofitamab 1fludarabine 1duvelisib 1cemiplimab 1belinostat 1X-Rays 1Specimen Handling 1Positron-Emission Tomography 1Photons 1Nivolumab 1Magnetic Resonance Spectroscopy 1MAC-ST-001 1Ipilimumab 1Immunoglobulin G 1Gemcitabine 1Fenretinide 1Disulfides 1CTLA-4 Antigen 1Biopsy 1Bendamustine Hydrochloride 110-propargyl-10-deazaaminopterin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Immunoblastic Lymphadenopathy × glofitamab × Clear all
NCT06393738 2026-02-10

A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.

Arvinas Inc.

Phase 1 Recruiting
255 enrolled
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡